Remove M&A Remove Medical Remove Negotiation
article thumbnail

Trends and Tips for Navigating Life Sciences M&A in 2024

JD Supra: Mergers

Dealmaking in the life sciences sector comes with characteristics not typically seen in more traditional mergers and acquisitions (M&A). Deals often involve negotiating around complexities associated with both the unique nature of assets of life sciences companies and the unique industry ecosystem that brings these assets to life.

M&A 165
article thumbnail

11 Lessons We Learned About Protecting Assets and Risks in M&A by Interviewing Joe Prencipe

How2Exit

11 Lessons We Learned About Protecting Assets and Risks in M&A by Interviewing Joe Prencipe. Ron Concept 1: Know The Risks of M&A When it comes to mergers and acquisitions (M&A), it is essential to understand the risks involved. -Ron M&A can be a great way to expand a business, but it can also be very risky.

M&A 130
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Mastering M&A Valuations: The Comprehensive Guide to Utilizing the Enterprise Value Calculator

Devensoft

Navigating M&A valuations with precision is paramount for informed decision-making. Whether you’re delving into M&A valuations for the first time or seeking to fortify your expertise, this guide offers comprehensive insights and actionable strategies to become a master of company valuation.

M&A 52
article thumbnail

The Cooley Outlook for 2018 M&A

Cooley M&A

What’s on tap for 2018 M&A? As an example, for California specific requirements, see our prior blog post Non-Competes for California Employees in M&A Deals: Don’t Fudge It. Approval of gross-ups in connection with a transaction typically involves a prior negotiation with the buyer.

M&A 52
article thumbnail

From $3M to $11M in 3 Years: Nikolas Hulewsky's Entrepreneurial Secrets Revealed!

How2Exit

After a decade in corporate healthcare, he ventured into entrepreneurship, successfully growing and eventually exiting multiple businesses, including a medical billing company and a home health and hospice service. The discussion delves into Nicholas's investment philosophy and approach to building a diverse portfolio within his hold company.

article thumbnail

Key Themes From Cooley’s M&A Dealmakers Roundtable: Insights on the Life Sciences M&A Market

Cooley M&A

On May 27th, Andy Pasternak, Executive Vice President, Chief Strategy Officer at Horizon Therapeutics and Eric Tokat, a partner in the healthcare practice at Centerview Partners joined Cooley M&A co-chair, Barbara Borden for a discussion of the life sciences M&A market, with a focus on business development. Credibility is key.

M&A 40
article thumbnail

Cooley’s 2019 Tech M&A Year in Review

Cooley M&A

Detailed below are our “notes from the field” for tech M&A in 2019. Tech M&A hit the global regulatory crosshairs in 2019 – creating a deal environment in which regulatory clearance, timing and scope of review quickly become one of the most critical factors in assessing transaction risk.

M&A 40